PubRank

A Goldhirsch

Author PubWeight™ 280.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002 4.32
2 Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000 3.79
3 Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999 3.50
4 Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996 3.30
5 Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004 3.29
6 Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001 3.24
7 Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992 3.17
8 Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998 3.03
9 Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008 2.91
10 Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006 2.72
11 Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008 2.26
12 Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 2001 2.05
13 Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol 1998 2.05
14 Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002 2.03
15 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012 1.96
16 Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000 1.92
17 Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000 1.91
18 Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 1991 1.88
19 Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000 1.81
20 Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000 1.79
21 Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012 1.79
22 Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001 1.79
23 Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999 1.77
24 Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003 1.75
25 Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 1992 1.70
26 Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996 1.70
27 Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2007 1.69
28 Outcome of special types of luminal breast cancer. Ann Oncol 2011 1.67
29 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008 1.66
30 Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med 1994 1.66
31 Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 2010 1.65
32 Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys 1996 1.63
33 Sudden death in cancer patient on high-dose domperidone. Lancet 1982 1.60
34 Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2005 1.60
35 A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996 1.58
36 Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996 1.58
37 The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990 1.56
38 Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007 1.54
39 Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011 1.50
40 The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials 1997 1.49
41 Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001 1.49
42 Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011 1.49
43 Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 2010 1.47
44 Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol 1999 1.47
45 Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol 1991 1.45
46 Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) Ann Oncol 1995 1.45
47 Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005 1.45
48 Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 2000 1.44
49 Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am 2006 1.43
50 Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann Oncol 2003 1.42
51 Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 1999 1.42
52 Treatment of advanced breast cancer: the good, the bad and the ugly. Ann Oncol 2005 1.42
53 Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. Ann Oncol 2001 1.41
54 The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol 1996 1.41
55 The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 1998 1.40
56 Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK) Eur J Cancer 1997 1.40
57 Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 2000 1.39
58 Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol 2006 1.38
59 High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001 1.38
60 A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989 1.37
61 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2006 1.30
62 Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 1987 1.28
63 Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009 1.28
64 Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009 1.26
65 Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986 1.25
66 The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1993 1.23
67 Can a clinical trial be the treatment of choice for patients with cancer? J Natl Cancer Inst 1988 1.23
68 Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 1996 1.21
69 New agents in non-small cell lung cancer. Cancer Treat Rev 1984 1.19
70 Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2012 1.19
71 High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 1998 1.19
72 Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002 1.17
73 Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 2007 1.17
74 First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996 1.15
75 A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001 1.14
76 Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 1993 1.12
77 Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011 1.12
78 First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994 1.11
79 Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003 1.11
80 Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004 1.10
81 A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986 1.10
82 Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. Ann Oncol 2003 1.08
83 Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997 1.08
84 Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 1996 1.07
85 Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 1997 1.07
86 Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007 1.06
87 Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 2006 1.06
88 Brain metastases in patients with advanced breast cancer. Anticancer Res 2007 1.06
89 A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009 1.05
90 The requirements of a specialist Breast Centre. Eur J Cancer 2013 1.04
91 Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group. Eur J Cancer 1992 1.03
92 Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998 1.03
93 Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008 1.02
94 Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features. Surg Neurol 1983 1.02
95 Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012 1.01
96 Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011 1.00
97 Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol 2004 1.00
98 Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992 0.99
99 Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 1985 0.99
100 Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2011 0.98
101 Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000 0.98
102 Radiotherapy to the conserved breast: is it avoidable if the cancer is small? J Natl Cancer Inst 1994 0.97
103 Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2005 0.96
104 Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 1995 0.96
105 Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 1990 0.96
106 Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. Breast 2004 0.95
107 CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007 0.94
108 Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 1998 0.94
109 Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984 0.94
110 Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 2000 0.94
111 Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol 2006 0.93
112 Acute cerebrovascular accident after treatment with cis-platinum and methylprednisolone. Oncology 1983 0.93
113 Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol 1998 0.93
114 Tumour dormancy and clinical implications in breast cancer. Ecancermedicalscience 2013 0.92
115 Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 2002 0.92
116 Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999 0.92
117 Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat 2012 0.92
118 Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat Rev 1993 0.92
119 Radiotherapy and chemotherapy in high-risk breast cancer. N Engl J Med 1998 0.91
120 Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J Clin Oncol 1997 0.91
121 Helix pomatia in breast cancer. Lancet 1991 0.91
122 Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 2011 0.90
123 Cox regression models for quality adjusted survival analysis. Stat Med 1993 0.90
124 Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. Eur J Surg Oncol 2005 0.90
125 Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005 0.90
126 Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011 0.90
127 Preoperative systemic treatment: prediction of responsiveness. Breast 2003 0.89
128 Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2000 0.89
129 Axillary node micrometastases and breast cancer. Lancet 1991 0.89
130 The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994 0.89
131 Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006 0.89
132 c-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1990 0.89
133 Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet 1999 0.88
134 Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 2005 0.88
135 Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer 2004 0.88
136 Immunohistochemical localization of galactosyltransferase in the normal human ovary and fallopian tube. J Histochem Cytochem 1984 0.88
137 HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? Ann Oncol 2012 0.88
138 A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 2009 0.88
139 Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 2007 0.88
140 Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast 2003 0.87
141 Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009 0.87
142 Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials 1993 0.87
143 Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol 2013 0.87
144 Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013 0.86
145 Henoch-Schönlein purpura (HSP) during treatment with anastrozole. Ann Oncol 2006 0.86
146 The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998 0.86
147 Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 1991 0.86
148 Adjuvant therapy of primary breast cancer. 4th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol 1992 0.86
149 Treatment of breast cancer in elderly patients. Lancet 1990 0.85
150 p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 2008 0.85
151 CMF revisited in the 21st century. Ann Oncol 2011 0.85
152 Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004 0.85
153 Why do women accept to undergo a nipple sparing mastectomy or to reconstruct the nipple areola complex when nipple sparing mastectomy is not possible? Breast Cancer Res Treat 2012 0.85
154 Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet 1987 0.85
155 Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 1984 0.85
156 Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Ann Oncol 1994 0.84
157 Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998 0.84
158 Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999 0.84
159 Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Ann Oncol 2001 0.84
160 Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 2007 0.84
161 The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009 0.84
162 The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol 1986 0.84
163 First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol 1986 0.83
164 Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 1997 0.83
165 Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg 2001 0.83
166 Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). Br J Cancer 1998 0.83
167 Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr 1986 0.83
168 Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 2001 0.82
169 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 2004 0.82
170 Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 1991 0.82
171 Taxanes as adjuvant for breast cancer. Lancet 2000 0.82
172 Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res 2000 0.82
173 Adjuvant therapy of primary breast cancer: closing summary. Recent Results Cancer Res 1993 0.82
174 The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 2009 0.82
175 Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 2005 0.82
176 Reporting and interpreting adjuvant therapy clinical trials. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr 1992 0.82
177 Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group. Eur J Cancer 2000 0.82
178 Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Ann Oncol 2003 0.82
179 Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012 0.82
180 Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2005 0.82
181 A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol 1982 0.82
182 Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. Ann Intern Med 1992 0.82
183 Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma. Ann Oncol 1999 0.81
184 Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 2009 0.81
185 Phase I study of the combination of monthly carboplatin and weekly cisplatin. Ann Oncol 1991 0.81
186 Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. Ann Oncol 2009 0.81
187 Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 2009 0.81
188 Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012 0.81
189 New drugs in small-cell lung cancer. Cancer Treat Rev 1986 0.81
190 Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 1981 0.81
191 Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans? Ann Oncol 2005 0.80
192 Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008 0.80
193 Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 1999 0.80
194 Warthin's tumor with Sjögren's syndrome and non-Hodgkin's lymphoma. Ear Nose Throat J 1979 0.80
195 Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients. J Natl Cancer Inst 2000 0.80
196 Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009 0.80
197 A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Stat Med 1995 0.79
198 Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat 2012 0.79
199 High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. Eur J Cancer 2013 0.79
200 Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. Anticancer Res 2002 0.79
201 Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer. Ann Oncol 2011 0.79
202 A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 1984 0.79
203 Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat 2000 0.79
204 [Colorectal cancer. Progress and unsolved problems]. Schweiz Med Wochenschr 1981 0.79
205 Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med 1987 0.79
206 Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat Rep 1984 0.79
207 Anthracyclines for gestational breast cancer: course and outcome of pregnancy. Ann Oncol 2008 0.79
208 Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004 0.79
209 Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J Chemother 2009 0.79
210 CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study. Ann Oncol 1990 0.79
211 Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1999 0.79
212 Clinical manifestation of severe hyperammonaemia in patients with multiple myeloma. Ann Oncol 1997 0.79
213 Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer 1998 0.78
214 Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet 1998 0.78
215 When can a second conservative approach be considered for ipsilateral breast tumour recurrence? Ann Oncol 2006 0.78
216 Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. J Clin Oncol 1993 0.78
217 Acute erythroleukemia following chemotherapy for Hodgkin's disease. Am J Med Sci 1980 0.78
218 Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr 1992 0.78
219 Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998 0.78
220 Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer 2008 0.78
221 Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer 2007 0.78
222 Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol 2000 0.78
223 An evaluation of tamoxifen dose escalation in advanced breast cancer. Am J Clin Oncol 1982 0.77
224 Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology. Cancer Chemother Pharmacol 1982 0.77
225 Estrogen receptor in malignant melanoma: fact or artefact? Eur J Cancer Clin Oncol 1983 0.77
226 Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. Med Pediatr Oncol 1981 0.77
227 Tailoring adjuvant treatments for the individual breast cancer patient. Breast 2003 0.77
228 Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 1997 0.77
229 Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 1996 0.77
230 Quality of life assessment in the adjuvant setting: is it relevant? International Breast Cancer Study Group. Recent Results Cancer Res 1998 0.77
231 Subcapsular liver metastasis in ovarian cancer. Computed tomography and surgical staging. Eur J Radiol 1985 0.77
232 Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 1997 0.76
233 Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treat Rev 1982 0.76
234 Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat Rev 1998 0.76
235 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol 2013 0.76
236 Adjuvant systemic therapy: the issues of timing and sequence. Recent Results Cancer Res 1996 0.76
237 Breast cancer: relevance of estrogen receptor determination at relapse. J Clin Oncol 1997 0.76
238 Understanding adjuvant chemotherapy for breast cancer. N Engl J Med 1994 0.76
239 Computed tomography prior to second-look operation in advanced ovarian cancer. Obstet Gynecol 1983 0.76
240 Can tamoxifen relieve motion sickness? Ann Oncol 2005 0.76
241 [Unusual autoimmune and neoplastic associated diseases in Sjogren's syndrome]. Schweiz Med Wochenschr 1979 0.75
242 Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology. Ecancermedicalscience 2008 0.75
243 QTc prolongation assessment in anticancer drug development: clinical and methodological issues. Ecancermedicalscience 2009 0.75
244 Correlation between administered treatment and patient's living will. Ecancermedicalscience 2009 0.75
245 The duration of a life of quality should become the focus of "quality-of-life" studies. J Clin Oncol 1989 0.75
246 Occult axillary lymph-node micrometastases in breast cancer. Lancet 1990 0.75
247 Premenopausal oopherectomy versus CMF chemotherapy in stage II breast carcinoma. The International Breast Cancer Study Group (IBCSG) Lancet 1993 0.75
248 Testing tumor dormancy in breast cancer. J Natl Cancer Inst 1994 0.75
249 [Preliminary results of a phase-II study with DDP (cis-diaminedichloro-platinum) in the small cell bronchogenic carcinoma]. Schweiz Med Wochenschr 1979 0.75
250 Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. Lancet Oncol 2001 0.75
251 Second tumours after breast cancer: is it still too soon to tell? Ann Oncol 1994 0.75
252 Adjuvant treatment for breast cancer: the overview. BMJ 1992 0.75
253 Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. Lancet 1990 0.75
254 Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). Ann Oncol 2004 0.75
255 Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses. Ann Oncol 1992 0.75
256 [Anaplastic small cell bronchus carcinoma. Diagnosis, treatment and prognosis]. Dtsch Med Wochenschr 1980 0.75
257 Abbreviated phase I clinical trial of i.v. mitozolomide. Cancer Treat Rep 1986 0.75
258 Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005 0.75
259 [Malignant non-Hodgkin's lymphoma in the otorhinolaryngologic region and the gastrointestinal tract. Results, indications and radiotherapy technic]. Schweiz Med Wochenschr 1980 0.75
260 Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Ann Oncol 1996 0.75
261 [Kidney and urinary tract complications in tumor patients]. Schweiz Med Wochenschr 1980 0.75
262 Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. Ann Oncol 2006 0.75
263 Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis. Oncology 1987 0.75
264 [Adjuvant therapy following breast-sparing surgery of breast carcinoma: priority to chemo- or radiotherapy?]. Ther Umsch 1988 0.75
265 Assessment of response in primary chemotherapy for breast cancer. Ann Oncol 1998 0.75
266 [Value of computed tomography for the assessment of lymph node metastases in ovarian cancer]. Rofo 1984 0.75
267 The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study. Psychooncology 2013 0.75
268 [Nausea and vomiting during chemotherapy of malignant tumors]. Schweiz Med Wochenschr 1981 0.75
269 Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma. Cancer Treat Rep 1980 0.75
270 Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. Semin Oncol 1997 0.75
271 Combination of chemotherapy with methotrexate, bleomycin, and cis-platinum, and radiation therapy for locally advanced carcinoma of the cervix. Am J Clin Oncol 1986 0.75
272 [Non-small cell bronchial carcinoma. Diagnosis, treatment and prognosis]. Dtsch Med Wochenschr 1980 0.75
273 Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992 0.75
274 [Phase-II-study with vindesine (desacetyl-vinblastine-amide-sulfate) in advanced malignant diseases]. Schweiz Med Wochenschr 1980 0.75
275 Hormono-chemotherapy in the treatment of advanced breast cancer. J Steroid Biochem 1985 0.75
276 Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. Breast 2000 0.75
277 Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer. Recent Results Cancer Res 1989 0.75
278 Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy. Oncology 1982 0.75
279 Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Support Care Cancer 1999 0.75
280 Psychological distress in cancer patients attending the European Institute of Oncology in Milan. Oncology 1999 0.75
281 [Status of chemotherapy in inoperable non-small cell bronchial carcinoma]. Schweiz Rundsch Med Prax 1983 0.75
282 Perioperative and conventionally timed chemotherapy in operable breast cancer: the Ludwig Breast Cancer Study V. Recent Results Cancer Res 1986 0.75
283 [Chemotherapy as primary therapy in non-radically operated ovarian cancer]. Onkologie 1985 0.75
284 A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone. Eur J Cancer Clin Oncol 1985 0.75
285 [The role of radiotherapy in the treatment of ovarian carcinoma: indications, techniques, results (author's transl)]. Schweiz Rundsch Med Prax 1981 0.75
286 Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 2006 0.75
287 Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil. Ann Oncol 2004 0.75
288 [Results of, and indications for adjuvant chemotherapy in breast cancer]. Schweiz Med Wochenschr 1981 0.75
289 [Gastrointestinal tumors. Prognostic factors and chemotherapy of today]. Dtsch Med Wochenschr 1981 0.75
290 [Polyneuropathy after cisplatin treatment]. Dtsch Med Wochenschr 1985 0.75
291 [Hormone receptors and breast cancer]. Gynakol Rundsch 1981 0.75
292 Clinical trials for clinicians. Chest 1989 0.75
293 [Stomach cancer. Spontaneous course, therapy and prognosis]. Schweiz Med Wochenschr 1982 0.75
294 The treatment of ovarian cancer by a multimodality approach: remission induction with chemotherapy--hexa PAMP and PAMP regimens--followed by whole-abdominal radiation. Onkologie 1985 0.75
295 New technologies for diagnosis and treatment of breast cancer: meeting highlights from the Fourth Milan Breast Cancer Conference (Milan, June 5-7, 2002). Breast 2003 0.75
296 Comparison of adjuvant therapies using quality-of-life considerations. Int J Technol Assess Health Care 1989 0.75
297 Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. Ann Oncol 2017 0.75
298 Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors. Oncol Rep 2011 0.75
299 [Ulcerated breast cancer of the young patient: a case report]. Helv Chir Acta 1992 0.75
300 [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213]. Schweiz Med Wochenschr 1981 0.75
301 [Principles of adjuvant drug therapy in breast cancer]. Gynakologe 1994 0.75
302 [New therapeutic concept for advanced ovarian cancer (FIGO IIb+c, III, IV)]. Gynakol Rundsch 1983 0.75
303 [Perfusion treatment of extremities in malignant melanoma. 9 year experience in 134 patients]. Helv Chir Acta 1983 0.75
304 Adjuvant therapy in postmenopausal node-positive breast cancer. J Clin Oncol 1985 0.75
305 Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma. Eur J Cancer 1980 0.75
306 Models for weighing benefits and toxicities. Cancer Treat Res 1992 0.75
307 How to compare quality of life of breast cancer patients in clinical trials. International Breast Cancer Study Group. Recent Results Cancer Res 1993 0.75
308 [Adjuvant treatment of breast cancer]. Gynakol Rundsch 1988 0.75
309 Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother Pharmacol 1982 0.75
310 [Computed tomography, primary laparotomy and second look surgery in ovarian carcinoma]. Rofo 1984 0.75
311 [Total abdominal irradiation following combination chemotherapy and second-look laparotomy in the treatment of advanced ovarian cancer]. Onkologie 1985 0.75
312 [Ovarian carcinoma: new prognostic and therapeutic viewpoints]. Schweiz Med Wochenschr 1980 0.75
313 Post-operative adjuvant trials in breast cancer--the Swiss group and the Ludwig International group. Experientia Suppl 1982 0.75
314 [Malignant melanoma: spontaneous course, therapy and prognosis]. Schweiz Med Wochenschr 1980 0.75
315 Perioperative and conventionally timed chemotherapy in operable breast cancer. Recent Results Cancer Res 1985 0.75
316 Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. Anticancer Res 2001 0.75
317 Parathyroid hormone-related protein in metastatic breast cancer induced hypercalcemia: a case report. Ann Oncol 2000 0.75
318 High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland. Bone Marrow Transplant 1997 0.75
319 [Vindesine, a new cytostatic agent from the vinca alkaloids]. Dtsch Med Wochenschr 1980 0.75
320 Meta-analysis in clinical research. Ann Intern Med 1988 0.75
321 An enzyme-linked immunosorbent assay for lactose synthase (galactosyltransferase) in serum and its application as a tumor marker in ovarian carcinoma. Clin Chem 1983 0.75
322 [Malignant non-Hodgkin lymphomas of the lymphoid ring, paranasal sinuses and salivary glands: results of radiation therapy from 1951 to 1976 (author's transl)]. Strahlentherapie 1980 0.75
323 [Adjuvant chemotherapy in soft tissue sarcomas]. Schweiz Med Wochenschr 1980 0.75
324 [Nausea and vomiting in tumor patients]. Schweiz Rundsch Med Prax 1983 0.75
325 A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer. Anticancer Res 2006 0.75
326 Adjuvant treatment in operable breast cancer. J Steroid Biochem 1985 0.75
327 The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. Acta Oncol 2007 0.75
328 Endocrine adjuvant therapy for breast cancer. Lancet 1985 0.75
329 [New developments in the chemotherapy of ovarian cancer (author's transl)]. Schweiz Rundsch Med Prax 1981 0.75
330 The Breast International Group. a new spirit of collaboration in breast cancer research for the new millennium. Eur J Cancer 2000 0.75
331 Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy, and second-look laparotomy. J Cancer Res Clin Oncol 1984 0.75
332 Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen) Ann Oncol 1999 0.75
333 [Ovarian carcinoma: epidemiology, natural history and preoperative staging (author's transl)]. Schweiz Rundsch Med Prax 1981 0.75
334 [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses]. Dtsch Med Wochenschr 1981 0.75
335 [Prolymphocytic leukaemia: a new clinical entity (author's transl)]. Dtsch Med Wochenschr 1977 0.75
336 [Prevention of cytostatic-related hair loss by hypothermia of a hairy scalp using a cooling cap]. Schweiz Med Wochenschr 1982 0.75
337 Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer. Semin Oncol 1995 0.75
338 Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Eur J Cancer Clin Oncol 1983 0.75
339 [Treatment and prognosis of superior vena caval syndrome in small-cell anaplastic carcinoma of the lung (author's transl)]. Klin Wochenschr 1981 0.75
340 Treatment of soft tissue malignancies of the extremities by regional perfusion. Antibiot Chemother (1971) 1988 0.75
341 [Bone destructive foci as precursors of the blastic crisis in chronic myelocytic leukemia]. Schweiz Med Wochenschr 1977 0.75
342 A phase I trial of marcellomycin with a weekly dose schedule. Eur J Cancer Clin Oncol 1983 0.75
343 [Central nervous system metastases in small cell lung cancer]. Schweiz Med Wochenschr 1981 0.75
344 Early-onset thrombocytopenia in the chemotherapy of testicular teratoma. Eur J Cancer Clin Oncol 1983 0.75
345 Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration. Ann Oncol 1996 0.75
346 [Can small cell bronchial carcinoma be cured today?]. Schweiz Rundsch Med Prax 1983 0.75
347 Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients. Recent Results Cancer Res 1984 0.75
348 [Intratumoral regional differences in hormone receptor status of breast cancer]. Geburtshilfe Frauenheilkd 1984 0.75
349 From the overview to the patient: how to interpret meta-analysis data. Recent Results Cancer Res 1993 0.75
350 [High-dosage methylprednisolone as an antiemetic in cytostatic-induced vomiting]. Schweiz Med Wochenschr 1983 0.75
351 Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma. J Cancer Res Clin Oncol 1984 0.75
352 [Adjuvant therapy in Operable non-small cell lung cancer]. Schweiz Rundsch Med Prax 1983 0.75
353 Mitomycin, hexamethylmelamine, and vindesine as second-line treatment for small cell cancer of the lung. Cancer Treat Rep 1982 0.75
354 Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Ann Oncol 2012 0.75
355 Old and new trends in the adjuvant treatment of early breast cancer. Ann Oncol 1991 0.75
356 [Ultrasonic diagnosis of ovarian carcinoma]. Schweiz Med Wochenschr 1983 0.75
357 "The only thing I know is that I know nothing": 5-fluorouracil in human milk. Ann Oncol 2012 0.75
358 Breast cancer at the end of a successful century: meeting highlights from the First Milan Breast Cancer Conference and discussion paper for the Second Conference (Milan, 14-16 June, 2000). Breast 2000 0.75
359 CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. Ann Oncol 2004 0.75